4:25 PM
 | 
Dec 11, 2017
 |  BC Extra  |  Clinical News

argenx rises on ARGX-113, ARGX-110 readout

argenx S.E. (Euronext:ARGX; NASDAQ:ARGX) jumped $24.02 (79%) to $54.47 on NASDAQ Monday after reporting data on its two lead compounds, efgartigimod (ARGX-113) and ARGX-110. The biotech gained €14.20 (56%) to €39.40 on Euronext.

Of 24 myasthenia gravis patients in a Phase II study, 75% of patients treated with efgartigimod achieved at least a 2 point reduction from baseline in the Myasthenia Gravis Activity-of-Daily-Living (MG-ADL) score vs. 25% of placebo-treated patients (p=0.0391). Efgartigimod was well tolerated...

Read the full 355 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Extra

Article Purchase

$35 USD
More Info >